Victor Levin, M.D.
Dr. Levin is a practicing physician at the Kaiser Permanente Redwood City Hospital Department of Neurosurgery with an emphasis on primary malignant brain tumors. He is a Professor Emeritus and former Chair the Department of Neuro-Oncology for The University of Texas M. D. Anderson Cancer Center. Dr. Levin has previously held positions as Staff Associate in the Laboratory of Chemical Pharmacology of the U.S. National Cancer Institute, where he was involved in some of the original research related to VAL-083 and as a Professor in the Departments of Neurological Surgery, Neurology, Pharmaceutical Chemistry, and Pharmacology at the University of California San Francisco. Dr. Levin holds B.S. and M.D. degrees from the University of Wisconsin and neurology residency at the Massachusetts General Hospital.
James Perry, M.D., FRCPC
Dr. Perry is the Chair the Canadian Brain Tumour Consortium, a Canadian national not-for-profit investigator network where he currently lead or co-lead several international collaborative clinical trials. He is an Associate Scientist, Clinical Integrative Biology in the Odette Cancer Research Program at Sunnybrook Research Institute and an Associate Professor, Department of Medicine – Division of Neurology at the University of Toronto, where is research focuses on brain tumor treatment and patient care. Dr. Perry received his medical degree from the University of Toronto and is a neurology Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC).
Ms. Christine Charette
Ms. Christine Charette served as a leading Canadian Equity Analyst of Biotechnology and Pharmaceuticals Research for BMO Capital Markets Canada where she was selected as a top life sciences analyst by Brendan Wood International several years in a row. She brings a broad range of experience in evaluating technologies and business strategies on behalf of institutional and retail investors.
Dr. Dan Zhang, M.D., Ph.D., MPH
Dr. Zhang is the Chairman Chief Executive Officer of Fountain Medical Development, and a member of the Chinese State Food and Drug Administration (SFDA) Oncology Advisory Board. Dr. Zhang was previously vice president at the Quintiles Transnational Corp., responsible for the planning and implementation of business development strategies in Greater China Area. Dr. Zhang received received his M.D. from Peking Union Medical College. He continued his study at the Harvard School of Public Health and received an MPH in health policy and management. Dr. Zhang continued his training at the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998 and is working on his Ph.D. dissertation in the field of health economics and finance.
Dr. Sol Barer, Ph.D.
Dr. Barer is a Senior Advisor and Former Chairman of Celgene. He was Chairman and Chief Executive Officer from May 1, 2006 until June 16, 2010 and Executive Chairman subsequently until January 1, 2011. Previously he was appointed President in 1993 and Chief Operating Officer in 1994 before assuming the CEO position. He also served as Senior Vice President, Science and Technology, and Vice President/ General Manager, Chiral Products, from October 1990 to October 1993, and Vice President, Technology, from September 1987 to October 1990. Dr. Barer received a Ph.D. in Organic Chemistry from Rutgers University and B.S. from Brooklyn College.